Myelodysplastic Syndromes (MDS) Clinical Trials

Myelodysplastic syndromes are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and a variable risk of transformation to acute myeloid leukemia. The bone marrow produces abnormal (dysplastic) blood cell precursors that fail to mature properly, resulting in low counts of red blood cells (anemia), white blood cells (neutropenia), and/or platelets (thrombocytopenia). MDS is classified into several subtypes based on the number of dysplastic cell lines, blast percentage, cytogenetic abnormalities, and molecular mutations.

The most common symptoms of Myelodysplastic Syndromes include Fatigue and weakness from anemia, Shortness of breath during normal activities, Easy bruising or unusual bleeding, Frequent or severe infections, Pale skin appearance, among others. Myelodysplastic Syndromes affects approximately 10,000 to 15,000 new cases annually in the U.S.; estimated 60,000 to 170,000 Americans living with MDS. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Myelodysplastic Syndromes from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Clinical trials for myelodysplastic syndromes are testing novel approaches including targeted therapies based on specific molecular mutations, immune checkpoint inhibitors, and next-generation hypomethylating agents. Luspatercept and other erythroid maturation agents continue to be studied in expanded MDS populations.

Yes. As of September 2026, Trial Friend lists 1 FDA-approved drug used to treat Myelodysplastic Syndromes: Rytelo (imetelstat), first approved in 2024.

Each has its own page with what the label covers, side effects and how it is given, and the Treatments section of this page adds any further approved drugs found in FDA labeling data.

Myelodysplastic Syndromes arises from acquired (somatic) genetic changes in the affected cells, rather than from an inherited variant. A clonal bone marrow cancer diagnosed by marrow biopsy with cytogenetics; about half of patients show a chromosomal abnormality such as del(5q), -7 or +8, and about 90% of cases are de novo with no inherited cause. The condition affects approximately 10,000 to 15,000 new cases annually in the U.S.; estimated 60,000 to 170,000 Americans living with MDS.

For Myelodysplastic Syndromes the genetic testing that matters is usually of the tumor or affected blood cells rather than inherited DNA. A clonal bone marrow cancer diagnosed by marrow biopsy with cytogenetics; about half of patients show a chromosomal abnormality such as del(5q), -7 or +8, and about 90% of cases are de novo with no inherited cause.

Those results guide treatment choice and are often the entry requirement for targeted-therapy trials, so ask whether the biopsy was sent for molecular testing and request the report. The Genetic Testing section of this page lists laboratories in the NIH Genetic Testing Registry.

Eligibility for Myelodysplastic Syndromes clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Myelodysplastic Syndromes clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.